Osteogenesis Imperfecta Explained: COL1A1/COL1A2, Brittle Bones, Blue Sclerae, Dentinogenesis Imperfecta and Treatment

What Is Osteogenesis Imperfecta?

Central Teaching Distinction

This should be established near the beginning.

Hypophosphatasia primarily teaches:

Osteogenesis imperfecta primarily teaches:

The central mechanism is:

Opening — Use This Content

A patient has repeated fractures after minimal trauma.

The immediate questions may include:

• osteoporosis?
• nutritional bone disease?
• non-accidental injury?
• another metabolic bone disorder?

But if the patient also has features such as:

• blue or gray sclerae;
• dentinogenesis imperfecta;
• short stature;
• skeletal deformity;
• ligamentous laxity;
• hearing loss;
• or a family history of similar fractures;

another diagnosis becomes particularly important:

Osteogenesis imperfecta, or OI, is a genetically heterogeneous group of disorders characterized principally by:

The most familiar forms result from pathogenic variants involving:

or:

which encode components of:

COL1A1/COL1A2-related OI ranges from mild disease with relatively few fractures and normal lifespan to severe progressively deforming disease and perinatally lethal forms. (NCBI)

The central clinical reasoning sequence is:

Type I Collagen and Bone Matrix

What Is Type I Collagen?

Type I collagen is a major structural protein of:

• bone;
• dentin;
• sclera;
• tendons;
• ligaments;
• skin;
• other connective tissues.

This explains an important principle:

A collagen abnormality can produce manifestations in multiple tissues.

Type I Collagen Structure

Type I collagen is a triple-helical molecule composed primarily of:

plus:

The genes are:

These chains assemble into the type I collagen triple helix.

The required memory is:

Bone Matrix Versus Mineral

This distinction is critical.

Normal bone contains:

Organic matrix

Dominated by:

plus other proteins.

Mineral

Predominantly:

The collagen matrix provides a structural framework within which mineral is deposited.

Therefore bone strength depends on:

In OI:

In osteomalacia:

COL1A1, COL1A2 and Bone Fragility

Molecular Mechanism

Quantitative Versus Qualitative Collagen Defects

This is an important advanced concept.

Some variants primarily result in:

Other variants produce:

These mechanisms help explain some genotype–phenotype relationships.

A classic teaching simplification is:

Quantitative defect

Often associated with:

Qualitative structural defect

Can produce:

But immediately state:

This is not a universal rule for every variant.

Genetics and Inheritance

Genetics

COL1A1/COL1A2-related OI is generally:

The diagnosis of COL1A1/COL1A2-related OI can be established in a patient with compatible clinical/radiographic manifestations by identifying an appropriate heterozygous pathogenic or likely pathogenic variant in COL1A1 or COL1A2. (NCBI)

However:

Other genes can produce OI or OI-like phenotypes through abnormalities involving:

• collagen processing;
• collagen modification;
• bone formation;
• osteoblast function;
• mineralization-related pathways.

De Novo Disease

An affected child may have:

because a pathogenic variant may arise:

Therefore:

This is particularly important when evaluating a child with unexplained fractures.

Parental Mosaicism

Recurrence can occasionally occur even when parents appear clinically unaffected and routine blood testing does not demonstrate the child's variant because of:

Therefore recurrence counseling should be individualized by genetics professionals.

Clinical Spectrum

Severity ranges from:

Mild fracture predisposition

Moderate disease

Progressive skeletal deformity

Severe perinatal disease

Perinatal lethality

The 2025 GeneReviews update emphasizes that the traditional clinical types remain useful but overlap substantially. (NCBI)

Types of Osteogenesis Imperfecta

For COL1A1/COL1A2-related OI, teach the four familiar clinical phenotypes.

Not every patient fits neatly into one category. (NCBI)

Type I OI

Type I — Classic Non-Deforming OI With Blue Sclerae

This is generally the mildest classic COL1A1/COL1A2 phenotype.

Features may include:

• fractures with minimal trauma;
• blue/gray sclerae;
• relatively mild or absent long-bone deformity;
• near-normal or mildly reduced stature;
• variable dentinogenesis imperfecta;
• ligamentous laxity;
• hearing loss later in life.

Fracture frequency may be greatest in childhood and may decrease after puberty, although fractures can continue throughout life.

Type I disease does not exclude severe complications in every patient.

Why Are The Sclerae Blue?

The sclera normally contains abundant type I collagen.

When scleral collagen is altered or the sclera is relatively thin/translucent, underlying pigmented structures become more visible.

Clinically this creates:

They may occur in other conditions.

Type II OI

Perinatally lethal OI represents an extremely severe phenotype.

Potential findings include:

• severe skeletal fragility;
• multiple fractures before birth;
• markedly abnormal bone mineralization/appearance;
• severe long-bone deformity;
• short limbs;
• small thorax;
• respiratory compromise.

The major life-threatening problem is often:

related to severe thoracic skeletal disease and pulmonary consequences.

Not every infant historically classified as Type II necessarily dies immediately; contemporary supportive care and phenotypic overlap make counseling more nuanced. GeneReviews emphasizes individualized neonatal counseling and uncertainty in outcome. (NCBI)

Type III OI

Type III is characterized by severe skeletal disease in individuals surviving the neonatal period.

Features may include:

• recurrent fractures from early life;
• progressive long-bone deformity;
• very short stature;
• scoliosis;
• vertebral compression;
• impaired mobility;
• chest-wall deformity;
• respiratory complications;
• variable scleral coloration;
• dentinogenesis imperfecta.

Memory:

Type IV OI

Type IV has:

Features may include:

• recurrent fractures;
• short stature;
• variable long-bone deformity;
• vertebral compression;
• dentinogenesis imperfecta in some patients;
• sclerae that are usually normal or become less blue with age.

Memory:

Fractures and Bone Deformity

Fractures

The hallmark of OI is:

Fractures may occur:

• after minimal trauma;
• after ordinary childhood activity;
• recurrently;
• in multiple bones.

Extremity fractures are particularly common in COL1A1/COL1A2-related OI. (NCBI)

But:

The whole phenotype matters.

Fracture Healing

Fractures generally can heal in OI.

The problem is not simply an inability to form callus.

However, repeated fractures plus abnormal mechanical loading can contribute to:

• deformity;
• refracture;
• loss of function;
• immobilization-related weakness.

Management therefore aims to restore function while minimizing unnecessary prolonged immobilization.

Bone Deformity

Repeated fractures and intrinsically weak bone can produce:

• bowing of long bones;
• angular deformity;
• limb-length abnormalities;
• scoliosis;
• kyphosis;
• chest-wall abnormalities.

Severe deformity is particularly important in progressively deforming OI.

Short Stature

Short stature may result from:

• abnormal skeletal growth;
• vertebral compression;
• long-bone deformity;
• repeated fractures;
• severe disease burden.

Severity varies markedly.

Mild Type I disease may have relatively normal stature.

Dentinogenesis Imperfecta

Dentinogenesis Imperfecta

OI may affect dentin because:

Dentinogenesis imperfecta may produce teeth that are:

• gray;
• brown;
• translucent;
• structurally fragile;
• prone to wear;
• prone to breakage.

GeneReviews identifies DI as an important but variable feature of COL1A1/COL1A2-related OI. (NCBI)

Oi Dental Disease Versus HPP Dental Disease

This distinction is mandatory.

Osteogenesis imperfecta

Primary dental problem:

→ dentinogenesis imperfecta.

Hypophosphatasia

Characteristic dental mechanism:

→ premature root-intact tooth loss.

Therefore:

Hypophosphatasia Explained

Hearing Loss and Joint Laxity

Hearing Loss

Hearing impairment may develop, particularly later in life.

It may be:

• conductive;
• sensorineural;
• mixed.

Therefore:

Hearing symptoms should not be dismissed as unrelated.

GeneReviews identifies hearing loss, commonly developing in adulthood, as a recognized manifestation. (NCBI)

Ligamentous Laxity And Joints

Abnormal connective tissue may produce:

• ligamentous laxity;
• joint hypermobility;
• instability;
• pain;
• functional impairment.

This is another reason OI should not be conceptualized only as “bones that fracture.”

Muscle Weakness And Mobility

Patients may have:

• muscle weakness;
• reduced endurance;
• altered gait;
• impaired mobility;
• reduced physical activity after repeated fractures.

This can create a cycle:

Therefore rehabilitation is a core component of management. (NCBI)

Spine and Respiratory Disease

Spine

Spinal manifestations may include:

• vertebral compression fractures;
• scoliosis;
• kyphosis;
• reduced trunk height.

Progressive scoliosis is particularly important in severe disease and can contribute to:

Basilar Impression

Some patients can develop craniovertebral abnormalities including:

Potential consequences can include neurological symptoms.

Symptomatic craniovertebral disease requires specialist evaluation in an experienced center.

GeneReviews recommends specialist surgical management when symptomatic. (NCBI)

Respiratory Disease

Respiratory problems can result from several interacting mechanisms:

• abnormal chest-wall geometry;
• scoliosis;
• reduced thoracic volume;
• respiratory muscle effects;
• intrinsic pulmonary/connective-tissue abnormalities in severe disease.

Therefore:

Severe respiratory involvement is a major contributor to morbidity.

Cardiovascular/Connective-Tissue Context

Because type I collagen is widespread, cardiovascular manifestations can occur in OI.

When to Suspect OI

• minimal trauma;
• recurrent fractures;
• blue/gray sclerae;
• dentinogenesis imperfecta;
• short stature;
• long-bone deformity;
• scoliosis;
• ligamentous laxity;
• hearing loss;
• family history.

But:

Laboratory Tests

Laboratory Tests

Routine biochemical testing is important mainly to:

In COL1A1/COL1A2-related OI, typical biochemical studies such as:

• calcium;
• phosphate;
• vitamin-D-related testing;
• alkaline phosphatase;

may be normal outside situations such as fracture healing or other coincident abnormalities.

Therefore:

This contrasts strongly with HPP, where persistently low ALP is a central biochemical clue. (NCBI)

ALP — Important Comparison

Osteogenesis imperfecta

Hypophosphatasia

Therefore:

Radiographic Findings

Radiographs

Radiographic findings depend on severity and age.

Potential findings include:

• fractures at different stages of healing;
• osteopenic appearance;
• long-bone bowing;
• deformity;
• vertebral compression;
• scoliosis;
• thin cortices;
• skull abnormalities;
• wormian bones.

No single radiographic sign is diagnostic.

Wormian Bones

Wormian bones are accessory ossicles within cranial sutures.

They may be seen in OI, particularly when numerous.

However:

They must be interpreted with the overall phenotype.

DXA

DXA may demonstrate reduced BMD.

It can be useful for:

• baseline skeletal assessment;
• longitudinal follow-up in selected patients;
• monitoring response to bone-directed treatment.

But:

and:

A patient can have clinically important skeletal fragility not explained by a single DXA value.

NIAMS includes bone-density testing as part of clinical assessment, while molecular testing can identify the underlying genetic disorder. (NIAMS)

Diagnosis and Genetic Testing

Diagnosis

The diagnostic process should integrate:

For COL1A1/COL1A2-related disease, identification of an appropriate pathogenic/likely pathogenic heterozygous variant in a compatible patient establishes the molecular diagnosis. (NCBI)

Genetic Testing

When OI is suspected, molecular testing may involve:

• COL1A1;
• COL1A2;
• broader multigene skeletal-fragility/OI panels when appropriate;
• more extensive genomic testing in unresolved cases.

The exact testing strategy depends on phenotype and local genetics practice.

Negative Genetic Testing

Reasons can include:

• testing limitations;
• genes not included;
• variant-detection limitations;
• alternative genetic skeletal-fragility disorders.

NIAMS similarly notes that a negative genetic test does not necessarily exclude an OI diagnosis. (NIAMS)

OI vs Hypophosphatasia

Implement this major table.

Bottom memory:

OI vs Osteomalacia

Osteomalacia Explained

OI vs Osteoporosis

Adults with OI can also develop age-related osteoporosis.

OI and Non-Accidental Injury

Multiple fractures in an infant or child may raise concern for:

OI may also cause multiple fractures.

Therefore clinicians must perform:

Features that may support OI include:

• compatible family history;
• blue sclerae;
• DI;
• generalized skeletal phenotype;
• characteristic deformity;
• molecular confirmation.

But:

and:

These are separate diagnostic questions requiring careful multidisciplinary evaluation.

Treatment Principles

Management Principles

There is currently no cure that universally corrects the underlying genetic defect in COL1A1/COL1A2-related OI.

Management aims to:

• reduce fracture burden;
• preserve mobility;
• prevent or limit deformity;
• maximize muscle strength;
• manage pain;
• maintain independence;
• optimize dental health;
• identify hearing problems;
• manage spinal disease;
• address respiratory complications;
• support quality of life.

Management is best:

GeneReviews emphasizes individualized multidisciplinary management. (NCBI)

Safe Handling

Infants and children with significant OI require:

Caregivers should be educated in safe handling.

Important principles include:

• broad hand support;
• gentle movements;
• avoiding unnecessary twisting or focal stress;
• supporting development rather than excessive restriction.

Avoid:

Excessive restriction can worsen weakness and functional limitation.

Physical Therapy and Mobility

Physical Therapy

Physical therapy is one of the most important management components.

Goals include:

• muscle strength;
• mobility;
• joint stability;
• motor development;
• functional independence;
• participation;
• prevention of contractures;
• recovery after fractures.

GeneReviews describes physical rehabilitation as a major therapeutic modality in OI. (NCBI)

Memory:

Immobilization

Fractures require appropriate stabilization.

However, unnecessarily prolonged immobilization may contribute to:

• muscle weakness;
• bone loss;
• delayed functional recovery.

Therefore:

GeneReviews recommends keeping immobilization as short as practical and restarting physical therapy promptly after cast removal. (NCBI)

Fracture and Orthopedic Management

Orthopedic Surgery

Orthopedic surgery may be required for:

• recurrent fractures;
• severe deformity;
• long-bone bowing;
• functional limitation;
• selected spinal disease.

A major technique in moderate/severe OI is:

The purpose is to:

• improve alignment;
• support long bones;
• facilitate function;
• reduce consequences of deformity.

GeneReviews describes intramedullary rodding as a mainstay of orthopedic management where indicated. (NCBI)

Telescoping Rods

In growing children, specialized rods may be designed to:

This can reduce the need for repeated replacement compared with fixed-length constructs in selected circumstances.

Bisphosphonates

Bisphosphonates

Create a major section.

Bisphosphonates are:

They are the most extensively used pharmacological bone-directed treatment in OI, particularly in patients with:

• vertebral fractures;
• frequent long-bone fractures;
• more severe disease.

They generally:

But:

and:

GeneReviews' 2025 update emphasizes that although BMD generally improves, evidence for fracture reduction—especially across all ages and phenotypes—is less definitive than the BMD effect. (NCBI)

Do Bisphosphonates Definitely Prevent Fractures?

Clinical studies support skeletal benefits, including increased BMD, and some observational/trial data suggest fracture benefits in selected populations.

However, available studies have limitations.

Therefore:

Avoid the inaccurate statement:

“Bisphosphonates completely prevent fractures in OI.”

Bisphosphonates: OI Versus HPP

OI

Bisphosphonates:

HPP

Antiresorptive therapy:

Therefore:

This reinforces why correct diagnosis matters.

Calcium, Vitamin D and Pain

Calcium And Vitamin D

Patients should have appropriate nutritional assessment and avoid clinically important deficiency.

But:

Avoid unnecessary excess.

Pain Management

Pain may arise from:

• acute fractures;
• deformity;
• chronic musculoskeletal stress;
• spinal disease;
• joint problems.

Management may combine:

• treatment of the underlying skeletal problem;
• rehabilitation;
• physical strategies;
• appropriate pharmacological analgesia;
• psychosocial support.

Dental and Hearing Care

Dental Management

Dental care should aim to preserve:

• primary dentition where possible;
• permanent dentition;
• function;
• occlusion;
• gingival health;
• appearance.

Dentinogenesis imperfecta may require specialist pediatric/restorative dental care.

GeneReviews recommends ongoing dental care appropriate to the OI phenotype. (NCBI)

Hearing Management

Patients should be evaluated when hearing concerns arise, with appropriate audiologic/ENT management.

Hearing loss may be:

• conductive;
• sensorineural;
• mixed.

Management depends on type and severity.

Respiratory Management

Respiratory assessment becomes particularly important in:

• severe OI;
• significant scoliosis;
• chest-wall deformity;
• symptoms of respiratory limitation.

Management should involve appropriate respiratory expertise.

Emerging Therapies

Emerging And Investigational Therapies

These are not established universal therapies.

Areas of study include:

• anabolic approaches;
• sclerostin inhibition;
• other pathways affecting bone formation/remodeling;
• molecular/genetic approaches.

GeneReviews' 2025 update describes several therapies under investigation, including anabolic approaches. (NCBI)

Teriparatide

Teriparatide has been studied particularly in adults with OI.

It has:

Some studies suggest differential response according to OI phenotype.

However:

Sclerostin Inhibition

Sclerostin inhibits Wnt-mediated bone formation.

Therefore blocking sclerostin is biologically attractive as an:

Several sclerostin-directed approaches have been investigated in OI.

Investigational agents are not established treatment.

Genetic Therapy

Gene editing, gene silencing and cell-based approaches are scientifically attractive because OI is fundamentally a genetic disorder.

However:

Genetic Counseling

Genetic Counseling

Genetic counseling should address:

• molecular diagnosis;
• inheritance;
• family testing;
• recurrence considerations;
• phenotypic variability;
• reproductive options where appropriate.

For typical heterozygous COL1A1/COL1A2 disease:

is central.

But parental mosaicism and de novo disease mean counseling should be individualized.

Pregnancy

Adults with OI can have successful pregnancies.

Pregnancy may nevertheless create additional issues involving:

• maternal skeletal health;
• mobility;
• respiratory status in severe disease;
• delivery planning;
• fetal inheritance risk.

Management should be individualized by appropriate obstetric and OI specialists.

The updated GeneReviews notes increased pregnancy complications but successful pregnancy is common. (NCBI)

Surveillance Principle

Surveillance should be:

Potential domains include:

• fracture history;
• growth;
• deformity;
• scoliosis;
• mobility;
• pain;
• DXA where clinically useful;
• dental health;
• hearing;
• respiratory function;
• neurological symptoms suggesting craniovertebral disease;
• functional independence.

The current GeneReviews provides age- and phenotype-dependent surveillance rather than a one-size-fits-all approach. (NCBI)

Diagnostic Algorithm

Implement prominently.

Look for:

Blue/gray sclerae

Dentinogenesis imperfecta

Short stature

Bone deformity

Joint laxity

Hearing loss

Family history

Fractures?

Deformity?

Vertebral compression?

Wormian bones?

Ca / PO₄ / ALP / vitamin-D context

Persistently low ALP?

Biochemistry not diagnostic?

COL1A1 / COL1A2 ± broader panel

Bottom memory:

Treatment Algorithm

Implement separately.

Fractures

Deformity

Mobility

Spine

Pain

Dental

Hearing

Respiratory

Most established:

Final:

Worked Clinical Cases

Case 1 — Child with recurrent fractures

A child has several low-trauma long-bone fractures plus blue sclerae.

Key thought

Assess the complete phenotype and proceed to appropriate molecular testing.

Case 2 — No family history

A child has fractures, DI and blue sclerae, but both parents are unaffected.

Wrong conclusion

“No family history, therefore not genetic.”

Correct principle

Case 3 — Mild adult disease

A 35-year-old reports numerous childhood fractures, few fractures after puberty, blue sclerae and adult-onset hearing difficulty.

Likely phenotype

Case 4 — Severe progressive disease

Child has fractures from infancy, marked long-bone bowing, very short stature and progressive scoliosis.

Likely phenotype

Case 5 — Normal sclerae

Patient has recurrent fractures, moderate short stature and DI but normal sclerae.

Lesson

Case 6 — Low ALP

Adult with fractures has repeatedly low ALP.

Wrong approach

“Every genetic fracture disorder is OI.”

Better approach

Case 7 — Dentinogenesis imperfecta

Child has gray translucent teeth plus recurrent fractures.

Lesson

Case 8 — Multiple fractures and safeguarding concern

Infant has multiple fractures.

Correct principle

One diagnosis should not be assumed solely to exclude the other.

Case 9 — Low BMD

Adult with genetically confirmed OI has low DXA BMD.

Wrong statement

“The DXA diagnosed OI.”

Correct statement

Case 10 — Bisphosphonate expectation

Parent asks whether bisphosphonate treatment will cure the child's OI.

Answer

It may improve skeletal measures and is widely used in selected significant OI, but it does not correct the COL1A1/COL1A2 defect.

Case 11 — Fracture immobilization

Child with OI has a treated long-bone fracture and remains inactive long after stabilization.

Lesson

Rehabilitation is important for restoring function.

Case 12 — Adult hearing loss

Adult with mild OI develops progressive hearing impairment.

Lesson

Hearing loss is a recognized extraskeletal manifestation.

Common Mistakes

Mistake 1

OI is simply osteoporosis in children.

Wrong.

Mistake 2

OI is primarily a calcium-deficiency disorder.

Wrong.

Mistake 3

OI is primarily defective mineralization.

Wrong.

Mistake 4

Every patient with OI has blue sclerae.

Wrong.

Mistake 5

Normal sclerae exclude OI.

Wrong.

Mistake 6

Every OI patient has dentinogenesis imperfecta.

Wrong.

Mistake 7

No family history excludes OI.

Wrong.

Mistake 8

All OI is caused by COL1A1/COL1A2.

Wrong.

Mistake 9

All COL1A1/COL1A2 variants produce identical severity.

Wrong.

Mistake 10

One fracture proves OI.

Wrong.

Mistake 11

Multiple fractures automatically prove OI.

Wrong.

Mistake 12

Normal calcium and phosphate exclude OI.

Wrong.

Mistake 13

Persistently low ALP is typical of classic OI.

Wrong.

Mistake 14

Low BMD on DXA diagnoses OI.

Wrong.

Mistake 15

A negative initial genetic test always excludes OI.

Wrong.

Mistake 16

Bisphosphonates correct the collagen mutation.

Wrong.

Mistake 17

Bisphosphonates cure OI.

Wrong.

Mistake 18

Children with OI should avoid all physical activity.

Wrong.

Mistake 19

Long immobilization always protects OI bone.

Wrong.

Mistake 20

OI affects only bone.

Wrong.

Osteogenesis Imperfecta in One Minute

Look for:

Blue sclerae

DI

Short stature

Deformity

Joint laxity

Hearing loss

Phenotypes:

Type I → mild / blue sclerae

Type II → perinatally lethal

Type III → progressively deforming

Type IV → variable / often normal sclerae

Treatment:

Final memory:

Frequently Asked Questions

Key Take-Home Messages

Osteogenesis imperfecta is fundamentally a disorder of:

The classic molecular pathway is:

But OI is not simply:

Type I collagen is distributed throughout connective tissues.

Therefore look for:

The clinical spectrum ranges from:

to:

to:

Diagnosis integrates:

Routine bone biochemistry may be normal.

Therefore:

And:

The distinction from hypophosphatasia is especially important:

whereas:

Management is multidisciplinary:

Bisphosphonates remain the most widely used pharmacological skeletal therapy in significant OI, but:

and:

The ultimate goal is:

Final memory:

and: